Loss of Biglycan Enhances Thrombin Generation in Apolipoprotein E-Deficient Mice: Implications for Inflammation and Atherosclerosis.

Arterioscler Thromb Vasc Biol

From the Institut für Pharmakologie und Klinische Pharmakologie, Universitätsklinikum der Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany (M.G., C.K., A.M.-B., K.F., S.H., J.M., L.-S.K., F.S., N.N., J.W.F.); Cardiovascular Research Institute Düsseldorf (CARID), Universitätsklinikum der Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany (M.G., C.K., A.M.-B., K.F., S.H., J.M., L.-S.K., F.S., N.N., A.P., J.W.F.); Klinik für Kardiologie, Pneumologie und Angiologie, Universitätsklinikum der Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany (A.P.); Pharmazentrum Frankfurt, Institut für Allgemeine Pharmakologie und Toxikologie/ZAFES, Klinikum der Goethe-Universität, Frankfurt am Main, Germany (J.Z.-B., L.S.); Institut für Hämostaseologie, Hämotherapie und Transfusionsmedizin, Universitätsklinikum der Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany (N.S.G., M.E.); King's British Heart Foundation Centre, King's College London, London, United Kingdom (P.S., X.Y., M.M.); and Division of Endocrinology and Molecular Medicine, Saha Cardiovascular Research Center, University of Kentucky, Lexington (L.R.T.).

Published: May 2016

Objective: Thrombin signaling promotes atherosclerosis by initiating inflammatory events indirectly through platelet activation and directly via protease-activated receptors. Therefore, endogenous thrombin inhibitors may be relevant modulators of atheroprogression and cardiovascular risk. In addition, endogenous thrombin inhibitors may affect the response to non-vitamin K-dependent oral anticoagulants. Here, the question was addressed whether the small leucine-rich proteoglycan biglycan acts as an endogenous thrombin inhibitor in atherosclerosis through activation of heparin cofactor II.

Approach And Results: Biglycan concentrations were elevated in the plasma of patients with acute coronary syndrome and in male Apolipoprotein E-deficient (ApoE(-/-)) mice. Biglycan was detected in the glycocalyx of capillaries and the subendothelial matrix of arterioles of ApoE(-/-) mice and in atherosclerotic plaques. Thereby a vascular compartment is provided that may mediate the endothelial and subendothelial activation of heparin cofactor II through biglycan. ApoE and Bgn double-deficient (ApoE(-/-)/Bgn(-/0)) mice showed higher activity of circulating thrombin, increased platelet activation and platelet adhesion in vivo, supporting a role of biglycan in balancing thrombin activity. Furthermore, concentrations of circulating cytokines and aortic macrophage content were elevated in ApoE(-/-)/Bgn(-/0) mice, suggesting a proinflammatory phenotype. Elevated platelet activation and macrophage accumulation were reversed by treating ApoE(-/-)/Bgn(-/0) mice with the thrombin inhibitor argatroban. Ultimately, ApoE(-/-)/Bgn(-/0) mice developed aggravated atherosclerosis.

Conclusions: The present results indicate that biglycan plays a previously unappreciated protective role during the progression of atherosclerosis by inhibiting thrombin activity, platelet activation, and finally macrophage-mediated plaque inflammation.

Download full-text PDF

Source
http://dx.doi.org/10.1161/ATVBAHA.115.306973DOI Listing

Publication Analysis

Top Keywords

platelet activation
16
apoe-/-/bgn-/0 mice
16
endogenous thrombin
12
thrombin
9
apolipoprotein e-deficient
8
thrombin inhibitors
8
thrombin inhibitor
8
activation heparin
8
heparin cofactor
8
apoe-/- mice
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!